Clinical Trial Update: N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial of Fenretinide LXS in patients with recurrent, refractory, or persistent neuroblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Fenretinide LXS (fenretinide)

Snippet

Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED